<DOC>
	<DOCNO>NCT02641041</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability single dose multiple dos BIIB033 administer healthy adult Japanese participant . The secondary objective study evaluate pharmacokinetics ( PK ) profile BIIB033 administer single multiple dos healthy adult Japanese participant assess single-dose multiple-dose immunogenicity BIIB033 .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Single Multiple Doses BIIB033 Healthy Japanese Participants</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Demyelinating Diseases</mesh_term>
	<criteria>Key Japanese subject must bear Japan , biological parent grandparent must Japanese origin . Subjects live Japan 5 year must significantly modify diet since leave Japan . Must nonsmoker light smoker ( &lt; 10 cigarette per day ) willing abstain use tobacco tobaccocontaining product Inpatient Period least 48 hour prior Day 1 , Day 14 ( Cohort 3 ) , outpatient visit . Must body mass index 18 32 kg/m2 , inclusive . Key History clinically significant cardiac , endocrine , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , major disease , determine Investigator . Serious infection ( e.g. , pneumonia , septicemia ) determine Investigator within 3 month prior Day 1 . Fever bacterial viral infection ( include upper respiratory tract infection ) within 2 week prior Day 1 . History severe allergic anaphylactic reaction . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Japanese</keyword>
	<keyword>Single Ascending Dose ( SAD )</keyword>
	<keyword>Multiple Ascending Dose ( MAD )</keyword>
</DOC>